Effect of colchicine and aspirin given together in patients with moderate COVID-19
Sunil Naik et al.,
Effect of colchicine and aspirin given together in patients with moderate COVID-19,
Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2023.101070, CTRI/2021/03/032060
RCT 122 hospitalized patients in India, showing improved recovery with colchicine treatment. All patients received aspirin. There was one death and higher progression in the colchicine arm, however 3 patients in the colchicine arm had baseline ordinal scores ≥5, while no patients in the control arm did.
risk of death, 169.4% higher, RR 2.69, p = 1.00, treatment 1 of 62 (1.6%), control 0 of 43 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
|
risk of progression, 108.1% higher, RR 2.08, p = 0.64, treatment 3 of 62 (4.8%), control 1 of 43 (2.3%).
|
recovery, 7.3% lower, RR 0.93, p = 0.21, treatment 62, control 43, relative improvement in ordinal score.
|
risk of no recovery, 15.0% lower, RR 0.85, p = 0.06, treatment 49 of 62 (79.0%), control 40 of 43 (93.0%), NNT 7.1, ordinal score ≤1.
|
recovery, 24.3% lower, RR 0.76, p = 0.02, treatment 62, control 43, relative improvement in CT score.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sunil Naik et al., 21 Jan 2023, Randomized Controlled Trial, India, peer-reviewed, 3 authors, trial CTRI/2021/03/032060.
Contact:
rmg.trial21@gmail.com.
Abstract: Journal Pre-proof
Effect of colchicine and aspirin given together in patients with moderate COVID-19
K. Sunil Naik, Niranjan Andhalkar, Sohal Pendse
PII:
S2451-8654(23)00016-9
DOI:
https://doi.org/10.1016/j.conctc.2023.101070
Reference:
CONCTC 101070
To appear in:
Contemporary Clinical Trials Communications
Received Date: 2 July 2022
Revised Date:
17 December 2022
Accepted Date: 14 January 2023
Please cite this article as: K. Sunil Naik, N. Andhalkar, S. Pendse, Effect of colchicine and aspirin given
together in patients with moderate COVID-19, Contemporary Clinical Trials Communications (2023), doi:
https://doi.org/10.1016/j.conctc.2023.101070.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2023 Published by Elsevier Inc.
Title: Effect of Colchicine and Aspirin given together in Patients with Moderate COVID19
Authors: aDr. K. Sunil Naik, bMr. Niranjan Andhalkar, bMr. Sohal Pendse
a. Research wing, second floor, beside FM ward, Government General Hospital, Srikakulam,
Andhra Pradesh – 532001, India.
b. 102 A/B, Park Plaza, Main Karve Nagar Chowk, Karve Nagar, Pune, Maharashtra 411052, India.
f
*Correspondence:
-p
ro
o
Mr. Sohal Pendse
Postal Address: 102 A/B, Park Plaza, Main Karve Nagar Chowk, Karve Nagar, Pune,
Jo
ur
na
Abstract:
lP
Email: rmg.trial21@gmail.com
re
Maharashtra 411052, India.
Background: The objective of the study was to evaluate the effect of Colchicine 0.5 mg. and
Aspirin 75 mg. oral tablets given together on management of moderate COVID-19.
Methods: The study was carried out in 122 moderate COVID-19 patients between ages 40 to
80 years in hospital, instructed to take either 1 tablet of Colchicine 0.5 mg. and Aspirin 75
mg. each (treatment group), or 1 tablet of Aspirin 75 mg (Control group), twice a day along
with standard of care.
Result: At the end of treatment, reduction was seen in the treatment group in score of 8-point
ordinal scale, troponin, D-Dimer, Hs-CRP from baseline. There was a fall of 51.1% among
control arm and 53.4% among treatment arm in 8-point ordinal score. The reduction in mean
D-Dimer was 37% in control group and 38.1% in treatment group. The mean reduction in CT
severity score in control group was 3.65 and in treatment group was 4.82, and the difference
between the two groups was statistically significant (P value= 0.018)
Conclusion: It was evident from CT scan scores that the treatment group has shown
significant improvement in the reduction of inflammation and other COVID-19 symptoms as
compared to the control group. The fall in Ferritin, Hs-CRP and D-Dimer level after
treatment were indicative of improvement in internal inflammatory response of body in
COVID-19 disease. As increased troponin levels indicate some degree of heart damage, the
fall in troponin levels indicated that test treatment improved heart health in COVID-19
f
patients.
-p
ro
o
CTRI/2021/03/032060
Keywords: COVID-19, Anti-inflammatory, Cardiac inflammation, NEWS, 8- point..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit